Journal Title
Title of Journal: Cancer Chemother Pharmacol
|
Abbravation: Cancer Chemotherapy and Pharmacology
|
Publisher
Springer-Verlag
|
|
|
|
Authors: Johnathan C Maher Awtar Krishan Theodore J Lampidis
Publish Date: 2003/11/07
Volume: 53, Issue: 2, Pages: 116-122
Abstract
In order to investigate the hypothesis that cells found in hypoxic areas of solid tumors are more sensitive to glycolytic inhibitors than cells growing aerobically we have previously characterized three distinct in vitro models A B and C that simulate this condition In all of the models it was shown that cells growing under hypoxic conditions are hypersensitive to the glycolytic inhibitor 2deoxydglucose 2DG However in those studies cytostatic and cytotoxic effects were not distinguished from one another Since successful treatment of cancer includes not only slowing down but also actually killing tumor cells studies were undertaken to assess the effects of 2DG on cell cycle progression and cell deathUsing flow cytometry and cell viability assays it was found that 2DG caused significantly greater cell cycle inhibition and cell death in all three hypoxic models as compared to aerobically growing control cells In model A a chemically induced model of hypoxia in which rhodamine123 is used to block oxidative phosphorylation 1200 μg/ml of 2DG was shown to induce more cell cycle arrest in late S/G2 and more cell death than in the aerobic cell counterpart treated with 3600 μg/ml 2DG In ρ0 cells which are genetically constructed to be unable to perform oxidative phosphorylation model B an even greater window of selectivity more than tenfold between hypoxic and aerobic cells was found when considering 2DG’s effects on cell cycle arrest and cell death In the environmental model model C where cells were grown under reduced amounts of external oxygen 01 hypersensitivity to the effects of 2DG with respect to cell cycle arrest and cell death were also observedOverall these results indicate that cells growing under anaerobic conditions respond with greater sensitivity to the effects of 2DG on cell cycle inhibition and cell death than those growing under aerobic conditions This supports our contention that glycolytic inhibitors added to standard chemotherapeutic protocols should increase treatment efficacy by selectively killing the slowgrowing cells which are found in the hypoxic portions of solid tumors while sparing most of the normal cells that are also slowgrowing but are living under aerobic conditions
Keywords:
.
|
Other Papers In This Journal:
- Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer
- The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia
- Central nervous system metastases in a cohort of metastatic breast cancer patients treated with trastuzumab
- Folate levels measured by LC–MS/MS in patients with colorectal cancer treated with different leucovorin dosages
- Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia
- Improved antiangiogenic and antitumour activity of the combination of the natural flavonoid fisetin and cyclophosphamide in Lewis lung carcinoma-bearing mice
- Phase I/II study of S-1 combined with biweekly irinotecan chemotherapy in previously treated advanced non-small cell lung cancer
- Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials
- Anticancer effect of ( E )-2-hydroxy-3′,4,5′-trimethoxystilbene on breast cancer cells by mitochondrial depolarization
- CEACAM1 and hollow spheroid formation modulate the chemosensitivity of colorectal cancer to 5-fluorouracil
- A phase I study of pegylated liposomal doxorubicin and temsirolimus in patients with refractory solid malignancies
- Clindamycin–paclitaxel pharmacokinetic interaction in ovarian cancer patients
- Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma
- Voreloxin, a first-in-class anticancer quinolone derivative, acts synergistically with cytarabine in vitro and induces bone marrow aplasia in vivo
- Dexrazoxane protects against doxorubicin-induced cardiomyopathy: upregulation of Akt and Erk phosphorylation in a rat model
- Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib
- Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies
- Hypericin—an inhibitor of proteasome function
- Pharmacokinetic analysis of carboplatin in patients with cancer who are undergoing hemodialysis
- Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors
- Elevated circulating monocyte chemoattractant protein 1 (MCP-1/CCL-2) level may be an unfavorable predictive factor to platinum- and taxane-based combination chemotherapy in patients with gastric cancer
- A phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone
- HMBA induces cell death and potentiates doxorubicin toxicity in malignant mesothelioma cells
- Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma
- Efficacy of combination chemotherapy with capecitabine plus cisplatin in patients with unresectable hepatocellular carcinoma
- In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin
- Artemisinin and its derivatives in cancer therapy: status of progress, mechanism of action, and future perspectives
- A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial
- Third-space fluid distribution of pemetrexed in non-small cell lung cancer patients
- SNS-314, a pan-Aurora kinase inhibitor, shows potent anti-tumor activity and dosing flexibility in vivo
- A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer
- Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice
- Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023
- Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models
- Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study
- Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer
- A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
- Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells
- Post-treatment with cotinine improved memory and decreased depressive-like behavior after chemotherapy in rats
- Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression
- The synergistic effect of dimethylamino benzoylphenylurea (NSC #639829) and X-irradiation on human lung carcinoma cell lines
- Phase 1 and dose-finding study of patritumab (U3-1287), a human monoclonal antibody targeting HER3, in Japanese patients with advanced solid tumors
- Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase
- Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma
- Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors
- The relative bioavailability of gefitinib administered by granular formulation
- Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors
- Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy
- Prediction of human pharmacokinetics and tissue distribution of apicidin, a potent histone deacetylase inhibitor, by physiologically based pharmacokinetic modeling
- Reversibility of liver failure secondary to metastatic breast cancer by vinorelbine and cisplatin chemotherapy
- Phase II study of rubitecan in recurrent or metastatic head and neck cancer
- Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer
- Efficacy and safety of ixabepilone in taxane-resistant patients with metastatic breast cancer previously treated with anthracyclines: results of a phase II study in Japan
- The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients
- Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency
- Influence of the etiology of liver cirrhosis on the response to combined intra-arterial chemotherapy in patients with advanced hepatocellular carcinoma
- A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomas
- Effect of cortisol on cell proliferation and the expression of lipoprotein lipase and vascular endothelial growth factor in a human osteosarcoma cell line
- A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer
- Successful treatment with a rituximab-based regimen of a splenic marginal zone lymphoma with villous lymphocytes in a very frail patient on maintenance dialysis
- Defining clinically relevant molecular subsets of lung cancer
- Circulating endothelial cells predict for response to bevacizumab-based chemotherapy in metastatic colorectal cancer
- Impact of patient ethnicity on the metabolic and immunologic effects of PI3K–mTOR pathway inhibition in patients with solid tumor malignancies
- A late phase II study of S-1 for metastatic pancreatic cancer
|